Treatment of Ocular Surface Squamous Neoplasia with Interferon Alpha-2b

Purpose: To study the efficacy and safety and of Interferon (IFN) alpha 2b for Ocular Surface Squamous Neoplasia (OSSN). Study Design: Non - Comparative Interventional Study. Place of Study: Mayo Hospital Lahore, Lahore General Hospital, Armed Forces Institute of Ophthalmology, Rawalpindi, Pakistan Duration of Study: study was conducted between the period of October 2010 to August 2016. Material and methods: Patients with suspected conjunctival growth underwent incisional biopsy after admission from out patient department. After confirming the diagnosis of Ocular Surface Squamous Neoplasia (OSSN), on Histopathology, case was inducted in the study. Intralesional / peri-lesional Interferon(IFN) Alpha-2b was given to the patients weekly along with interferon Alpha-2b topical drops four times daily, for Three 03 months. These patients were followed in Out Patient Department of respective hospitals and examined. For resolution or recurrence of lesion for at least three (03) months. And final results were compiled. Results: Study was conducted at Mayo Hospital Lahore, Armed Force institute of Ophthalmology, Rawalpindi and Lahore General Hospital, Lahore. Total Sample size of 90 (Ninety) Patients is estimated by using 95% confidence level, 10% absolute precision with expected percentage of Ocular surface squamous neoplasia as 91.6%. n= (Z1-α/2)2 X P X q / d2 Z1-α2 = Confidence level 95% = 1.96 P = Prevalence 91.6% q= 1-P d= Absolute precision 10% Out of these Twenty-nine, 29 were females and Fifty Nine, 59 were male patients. Non-Probability consecutive sampling was done. All patients tolerated and responded well to the treatment. There was recurrence in Eight 8 eyes. Conclusion: For the management of Ocular surface squamous Neoplasia IFN alpha 2 b is safe and effective choice with low recurrence rates.

Download Full-text

Topical Therapy for Ocular Surface Squamous Neoplasia

US Ophthalmic Review ◽

10.17925/usor.2013.06.02.154 ◽

2013 ◽

Vol 06 (02) ◽

pp. 154

Author(s):

Derek Bitner ◽

Donald U Stone ◽

◽

Keyword(s):

Ocular Surface ◽

Topical Therapy ◽

Genetic Defect ◽

Surgical Excision ◽

Treatment Modalities ◽

Ocular Surface Squamous Neoplasia ◽

Recurrence Rates ◽

Interferon Alpha 2B ◽

Complete Surgical Excision ◽

Treatment Paradigm

Ocular surface squamous neoplasia, or OSSN, is a clinical spectrum often encountered in ophthalmic practice. The incidence varies depending on the population being studied, but is more common among less pigmented males with increased occupational ultraviolet (UV) exposure as well as among those living in closer proximity to the equator. The incidence increases with age; in younger patients, the presence of OSSN is often associated with another underlying disorder, such as the genetic defect in xeroderma pigmentosum, or immunosuppression as is seen in patients infected with HIV. The challenges of complete surgical excision in patients with extensive tumors, in addition to the high recurrence rates in some series, led to a search for nonsurgical treatment modalities. In addition to avoiding surgery, topical agents may offer the additional benefit of treating clinically unapparent disease. Due to the theoretic advantages of topical chemotherapy, multiple agents have been used in both the primary and adjuvant treatment of OSSN. Mitomycin, interferon alpha-2b, and 5-fluorouracil have all been utilized with success; mitomycin may invoke a greater risk for limbal stem cell failure, and interferon is well tolerated and effective but more expensive. Future developments in imaging and chemotherapeutics will likely continue to alter the treatment paradigm for ocular surface tumors.

Download Full-text